[IPO] TomoCube "Irreplaceable HT Core Technology... Targeting Global Organoid Market"

Park Yong-geun, CEO of TomoCube.

"The holotomography technology possessed by Tomocube is an indispensable core technology in the era of 3D biology and regenerative medicine. Through this KOSDAQ listing, we will widely promote Tomocube's technological capabilities in the global market and transform into a global bio-imaging company that provides technological standards in the rapidly growing organoid and cell therapy markets."

Tomocube (Co-CEOs Park Yong-geun and Hong Ki-hyun), a specialized company in three-dimensional label-free cell imaging, held a press conference on the 23rd in Yeouido with the attendance of the CEO and key executives to announce its future strategies and vision following its KOSDAQ listing.

Tomocube's greatest competitive advantage lies in owning the original holotomography (HT) technology. Holotomography is Tomocube's proprietary technology that allows real-time, high-resolution observation of living cells or organoids without cell loss or deformation. Utilizing 3D imaging technology, it enables long-term observation of living three-dimensional cell structures and can detect intracellular toxicity that is difficult to find with conventional microscopes, making it applicable to organoids (organ-like structures/mini-organs created by culturing cells in 3D). Tomocube independently develops all theories, optics, hardware, software, and AI technologies related to holotomography, maintaining a super-gap in the global market through this.

Tomocube's holotomography technology is highly scalable because it is advantageous for real-time observation of 3D high-resolution images while growing organoids, which are human organ analogs. It is gaining attention in ▲organoids ▲IVF (in vitro fertilization) ▲cell therapy ▲new drug development, and recently, it has expanded its base by actively entering the bio sector as well as the hybrid bonding and semiconductor advanced packaging inspection markets, and the glass substrate (semiconductor glass substrate) inspection market.

Based on such unique competitiveness, sales have also shown steady growth. Tomocube's sales in 2023 reached 3.75 billion KRW, a 100.4% increase compared to the previous year, with exports accounting for 63.5%. The sales proportion of second-generation equipment increased from 34.4% in 2022 to 81.5% in 2023, driving overall sales growth. Recently, Tomocube plans to support sales growth by launching the ‘HT-X1 Plus,’ which features a field of view four times wider and high-speed scanning to enhance research efficiency.

Tomocube plans to use the funds raised from this listing for ▲global market expansion ▲capacity expansion due to front-end industry growth ▲research expenses for product and business expansion. Currently, it secures a diverse customer base through direct and indirect distribution networks in over 30 countries and plans to secure market position for future growth. Alongside this, as demand for Tomocube products is rapidly increasing in the bio and semiconductor inspection fields, it will also expand production facilities to meet this demand. Investments will also be made in R&D for product advancement and business expansion in bio and semiconductor inspection equipment.

Park Yong-geun, CEO of Tomocube, stated, "With Tomocube's unique holotomography technology, we are growing into a global deep-tech company encompassing not only the bio industry but also non-bio industries such as semiconductors and displays. After listing, we will strive to maximize sales growth and operating profit to realize the interests of shareholders and investors."

Meanwhile, Tomocube plans to offer 2 million shares through this listing. The expected public offering price per share ranges from 10,900 to 13,400 KRW, with a total expected offering amount of approximately 21.8 to 26.8 billion KRW. Institutional demand forecasting is being conducted over five days until today, followed by general subscription on the 28th and 29th, aiming for listing on November 7. The lead underwriter is Daishin Securities.